about
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursDevelopment of 131I-tositumomab.Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Isotopic evaluation and therapy in patients with malignant endocrine disease.18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.Gastrinoma (duodenal and pancreatic).Targeted radionuclide therapy for neuroendocrine tumours: principles and application.123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.Re-assessing gallium-67 as a therapeutic radionuclide.Intra-arterial brachytherapy of hepatic malignancies: watch the flow.Role of SPECT/CT in differentiated thyroid cancer.Nuclear medicine training and practice in the UK.Targeted radionuclide therapy for bone metastases.Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.Cancer therapy using bone-seeking isotopes.Nuclear medicine innovations help (drive) healthcare (benefits).A practical guide to targeted therapy for bone pain palliation.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.Molecular radiotheragnostics in thyroid disease.Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients.Guidelines for the management of thyroid cancerPhase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyMeasurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy89Sr therapy: strontium plasma clearance in disseminated prostatic carcinomaGlomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidinePulmonary embolism. Is the clinical history a useful adjunct to aid the interpretation of the equivocal lung scan?Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy CommitteeRadionuclide therapyA survey of the role of the UK physicist in nuclear medicine: a report of a joint working group of the British Institute of Radiology, British Nuclear Medicine Society, and the Institute of Physics and Engineering in Medicine68Ga-DOTATATE PET in neuroectodermal tumours: first experienceThe qualified person in radiopharmacyThe diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer
P50
Q24685837-CF5426C5-B70C-4D44-9936-191ABACF1023Q33365537-A527A0DE-8C1E-4B7A-8D23-DE67B1AD10A8Q33834340-849FF987-4EDC-4588-AAF7-9C39F60F2F69Q34319015-29297913-6970-46A6-A6B0-AB4C88332417Q35335407-F2A0C46D-73B2-42FA-9233-C560C4559E3FQ35760798-71853CB8-2007-490D-9ADB-760E9CD2D28FQ36085312-A9F0C870-E379-48E9-9D71-3CFD00EE083BQ36741116-83A5BA48-BB73-43FC-B357-46490B0E201CQ37546563-CE4ADFAB-6000-4957-A439-C59562BAE68CQ37559805-E7EB7C26-EF8B-45AA-9250-1EF4FED78858Q37588379-BBCFE93A-9429-42E0-B064-1D6527639E9CQ37636841-2FF8646E-2C6D-40F0-ADF1-19E6BA9DEC46Q37798154-B4363AAA-3596-41D1-B102-DD9EB77F5DAFQ38016305-C556A1C4-2462-4509-9269-3ABCDCDBCDB6Q40290922-D2CBBBAD-ACCF-4269-A3B9-8B09BB763E9AQ40484426-A98E16E6-EE98-48F8-897D-8A7B8D8324A7Q41192078-957E0780-76E0-4096-B2F0-E55D7EB26032Q41205760-3C8100AF-D81A-4C6F-8155-3E6F83BD4A2AQ42757682-2A4B52CF-2B83-45C2-920E-6800A7D065CEQ44113777-7F9E3D20-29E7-4B45-A072-B6201BEAB300Q44123857-94515AF0-5DD4-482C-BE04-7DECD35BEF9CQ46666971-E27C5A33-06EA-4B10-80E6-F593056D5307Q46695937-CA49E698-982A-4328-BACB-CA190034E98AQ49642714-8525B552-7239-4446-B04B-197D0B1F5139Q50095193-1FE92F1B-0C4C-45D4-B7EB-593F7D81DC81Q50440257-F0E7DF42-B59D-4CF7-9453-22DB75C3CEFBQ50927431-E854FA72-6D09-4A11-8598-685DA4DCB934Q56554243-690AB96A-3B1A-4DC8-91FF-65C66D8A039DQ57271786-7C331FFA-3A37-42CC-94E8-97428D924401Q69273026-43264C3D-7007-4331-B586-BDEADB172FE7Q69329851-46497F8D-2FB4-4F34-A590-49E00A76CA61Q69406079-8F0A3A06-05EC-4CF9-8A5B-8A54B42164F1Q71626708-4C1A5492-DEB9-4F1D-9417-921C3A10F346Q74609060-92DC57DC-68E1-4098-9044-0CF654FB3248Q78208553-D57F0380-1E52-49E3-9D64-ED260AE45027Q78714891-30DFE341-0893-48B9-8D09-8371D641C546Q80112549-3B0A9CD7-4AA7-47DF-8615-83E20F197E2CQ82747133-A6493197-C01B-4338-BF7D-58A2207EDDC5Q84708376-B88EB86F-8615-4A9B-A51A-7518B0A0BDB6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Val Lewington
@ast
Val Lewington
@en
Val Lewington
@es
Val Lewington
@nl
type
label
Val Lewington
@ast
Val Lewington
@en
Val Lewington
@es
Val Lewington
@nl
prefLabel
Val Lewington
@ast
Val Lewington
@en
Val Lewington
@es
Val Lewington
@nl
P106
P1153
6701626224
P31
P496
0000-0002-8521-5478